Company
Profile
NEXT
Binhui Biopharmaceutical (Binhui Bio) was founded in 2010, by Dr. Binlei Liu, a key member of the original T-VEC development team. Binhui Bio is a high-tech enterprise specializing in the R&D, pilot production of innovative drugs and provision of biotechnology services. Binhui Bio has four technology platforms: oncolytic virus (OV) immunotherapy platform (oHSV2), nucleic acid platform, protein platform and cell therapy platform.
BS001 (OH2 injection), one of the company's OV products, has received 5 INDs and 1 orphan drug approval from NMPA and FDA since 2018 for cancer monotherapy and combination therapy. BS001 is the first HSV2-derived OV to enter clinical trials worldwide.
The company has established FDA and NMPA approved production process, and its integration of production and research can fully satisfy the requirements of both clinical development and the industrialization. Binhui Bio has a cGMP pilot plant with multiple production lines that can be simultaneously used. With its high-content cell imaging system, bioreactor, in vivo imager, AKTA chromatography purification system, flow cytometer, real-time qPCR machine, water-for-injection production system and filling system, and other facilities and equipments, Binhui can fully meet the needs of clinical drug production and product R&D.
Since the establishment, Binhui Bio has successively obtained investment from well-known venture capital such as Beijing Lampan, Shenzhen Fortune, Lepu Medical, Share Investment, Vertex Investment and Yangtze River Pharma, etc.
Management
Team
Product
PipelinesCandidates
Indication
Pre-clinical
IND
Dose Escalation (Phase I)
Dose Extension (Phase II)
Pivotal Study
(Phase III)
Melanoma
GBM
mCRC
Melanoma with αPD-1 failure
Sarcoma
Cholangiocarcinoma
Solid tumors(IIT)
Solid tumors
Solid tumors(IIT)
Solid tumors
Oncology/Aesthetic Medicine
Prophylactic Vaccine
Malignant pleural and abdominal effusions(IIT)
Malignant pleural and abdominal effusions
Note：BS001:oHSV2hGM-CSF，also named OH2 injection；BS006: oHSV2CD3-PD-L1; BS008 (Cocktail): BS001+BS006
Contact Us
BD Tel.：
0086-027-87326962Info Disclosure Tel.：
0086-027-87700600Website：
www.binhui-bio.comOffice Address：
D3-4 of OVU Technology City, Gedian Development Zone, Ezhou, Hubei ProvinceRegistered Address：
No. 666 Gaoxin Avenue, Donghu New Technology Development Zone, WuhanBD e-mail：
BD@binhui-bio.comInfo Disclosure e-mail：
binhui@binhui-bio.com
Official WeChat Account
Business and Market
BD Tel.：0086-027-87326962
Info Disclosure Tel.：0086-027-87700600
BD e-mail：BD@binhui-bio.com
Info Disclosure e-mail：binhui@binhui-bio.com
Please scan the code to follow our account
Dr. Binlei LIU
University of Southampton PhD / Postdoctoral Researcher
2000-2009: BIOVEX Ltd (U.K) | Senior scientist and Chief scientist of molecular biology | Core member of the original T-VEC (OncoVexGM-CSF) development team
BIOVEX’s T-VEC was acquired by Amgen for US$1 billion | Approved by the US FDA and EU EMA in 2015 and 2016 respectively | first oncolytic virus drug in the market in the developed countries
Led R&D team to establish an oncolytic herpes simplex virus type 2 based platform and other technology platforms for drug and vaccine development
Published 40+ research papers, multiple patent licenses
Zhizheng Fang
Professor
Engineer and Assistant Director of Wuhan Institute of Biological Products Co.,LTD.
Expert of National Drug Evaluation Committee
Editorial Board of International Journal of Biologicals
Expert of Hubei Province Science and Technology Office
Executive Director of Hubei Medical Association
Hanming Wang
25 years of experience in Sanofi-Pasteur, Pfizer, CRO and Biotech companies, familiar with the whole process from drug development to commercialization.
Obtained 13 vaccine/drug IND/BLA approvals.
Dr. Yan Xu
National Distinguished Expert (China).
Recombinant protein vaccine research.
Nova Biologiques Inc CSO, developed a virus-like particle platform.
Senior Scientist at Viropro Inc.
National Research Council of Canada, Post-doctorate in the field of biotechnology.
PhD, McGill University.
Dr. Yang Wang
PhD/Associate Professor
Oncolytic virus and cell therapy research
Awarded the title of “Chu Tian Xue Zi”
Admitted to the 3551 Talent Program
Led NSFC Project
Published a total of 23 SCI papers, as first author of 12 SCI
Dr. Han Hu
PhD/Associate Professor
Oncolytic virus and T cell therapy preclinical research
Awarded the title of “Nan Hu Xue Zhe”
Led NSFC Project
Published a total of 21 research papers, of which 12 were included in SCI
Normand Jolicoeur
Senior Technology Officer, National Research Council of Canada.
Nova Biologiques Inc, Chief Scientist.
Broad expertise in several fields related to biotechnologies and biopharmaceuticals.
Development of innovative solutions for a large number of biopharmaceutical companies.
Author of several patents on VLP and subunit vaccines.
